Afatinib vs Pyrotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline

Afatinib · Gilotrif

Marketed by Boehringer Ingelheim

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00949650 · Phase 3 · completed

The study randomly assigned 345 participants to afatinib or active chemotherapy, but it was open-label rather than blinded. Its hard clinical primary endpoint, centrally assessed progression-free survival, was statistically significantly better with afatinib, but the lack of blinding limits the strength of the evidence.

Next expected readout: December 2026 · NCT04413201 (registry estimate)

Reported efficacy

Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7) (met)

Result source: NCT01121393

Pyrotinib

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04447118 · Phase 3 · completed

The study randomly assigned 151 participants to pyrotinib or active treatment with docetaxel, with the primary endpoint assessed by an independent committee blinded to treatment assignment. Because results for the progression-free survival comparison have not been posted, the trial provides limited evidence at this time despite its randomized design.

Next expected readout: December 2026 · NCT05482568 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAfatinibPyrotinib
PFS, median11.2 vs 6.9vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
22 other results
—Not posted · NCT04447118
OS, median28.2 vs 28.2vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
10 other results
—Not posted · NCT04447118
ORR67.8% vs 23%vs Gemcitabine / Cisplatin40mg · n 242NCT01121393
14 other results
—Not posted · NCT04447118
Duration of response, median9.7 vs 4.3vs Gemcitabine / Cisplatin40mg · n 164NCT01121393
6 other results
  • 10.5 50 mg · n 69 · Phase 2 · secondary NCT00796549
  • 17.6 n 80 · Phase 2 · secondary NCT00525148
  • 9 Afa40+Ctx500 · n 126 · Phase 1 · secondary NCT01090011
  • 3.9 Afa40 Mono · n 37 · Phase 1 · secondary NCT01090011
  • 5.8 Afa40+Ctx500 · n 36 · Phase 1 · secondary NCT01090011
  • 0 Afa40+Ctx250 · n 4 · Phase 1 · secondary NCT01090011
—Not posted · NCT04447118

PFS, median

Afatinib
11.2 vs 6.9vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
22 other results
Pyrotinib
—Not posted · NCT04447118

OS, median

Afatinib
28.2 vs 28.2vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
10 other results
Pyrotinib
—Not posted · NCT04447118

ORR

Afatinib
67.8% vs 23%vs Gemcitabine / Cisplatin40mg · n 242NCT01121393
14 other results
Pyrotinib
—Not posted · NCT04447118

Duration of response, median

Afatinib
9.7 vs 4.3vs Gemcitabine / Cisplatin40mg · n 164NCT01121393
6 other results
  • 10.5 50 mg · n 69 · Phase 2 · secondary NCT00796549
  • 17.6 n 80 · Phase 2 · secondary NCT00525148
  • 9 Afa40+Ctx500 · n 126 · Phase 1 · secondary NCT01090011
  • 3.9 Afa40 Mono · n 37 · Phase 1 · secondary NCT01090011
  • 5.8 Afa40+Ctx500 · n 36 · Phase 1 · secondary NCT01090011
  • 0 Afa40+Ctx250 · n 4 · Phase 1 · secondary NCT01090011
Pyrotinib
—Not posted · NCT04447118
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Pyrotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Afatinib: 4 of 4 rows · Pyrotinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAfatinib
Dropout rate
n/a: no completion milestone40 mga
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
—50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—40 mg
NCT00525148 · Phase 2
—50 mg
NCT00525148 · Phase 2
100%40mg
NCT01121393 · Phase 3
n/a: no completion milestone
NCT01523587 · Phase 3
n/a: no completion milestone40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT01853826 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT01953913 · Phase 3 · registry result, not featured evidence
0%40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
28%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
—Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
0%
NCT02369484 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
0%Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
0%Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01074177 · Phase na · registry result, not featured evidence
Discontinued due to AEs
12.2%40 mga
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
—50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1%50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—40 mg
NCT00525148 · Phase 2
—50 mg
NCT00525148 · Phase 2
9.9%40mg
NCT01121393 · Phase 3
17.1%
NCT01523587 · Phase 3
20%40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
12.9%
NCT01853826 · Phase 3 · registry result, not featured evidence
3.7%
NCT01953913 · Phase 3 · registry result, not featured evidence
—40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
19.3%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
—Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
22.2%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
22.7%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
41.7%40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
33.3%30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
—
NCT02369484 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
25.8%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
5%50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
—50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
17%40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
—Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—
NCT01074177 · Phase na · registry result, not featured evidence
Serious AEs
31.4%40 mga
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
34.9%50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
30%40 mg
NCT00525148 · Phase 2
44.4%50 mg
NCT00525148 · Phase 2
16.7%40mg
NCT01121393 · Phase 3
44.4%
NCT01523587 · Phase 3
35%40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
43.8%
NCT01853826 · Phase 3 · registry result, not featured evidence
30.3%
NCT01953913 · Phase 3 · registry result, not featured evidence
21.4%40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
40.8%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
40.3%Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
55.6%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
22.7%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
33.3%40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
75%30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
33.3%40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
38.5%
NCT02369484 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
25.8%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
50.7%50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
46.3%50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
40.5%40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
0%Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
40%Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
75%Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
50%Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
32.4%Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
41.7%Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT01074177 · Phase na · registry result, not featured evidence
Most frequent reported AEs
40 mga
diarrhoea 94.3%
rash 63.3%
paronychia 57.6%
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 31 more results
50 mg/Day
diarrhoea 85.6% (placebo 9.2%)
rash 63.6% (placebo 11.8%)
paronychia 33.6% (placebo 0.5%)
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
40 mg
diarrhoea 96.7%
paronychia 66.7%
rash 66.7%
NCT00525148 · Phase 2
50 mg
diarrhoea 92.9%
paronychia 79.8%
rash 75.8%
NCT00525148 · Phase 2
40mg
diarrhoea 88.7%
rash 73.2%
paronychia 33.5%
NCT01121393 · Phase 3
diarrhoea 72.4%
rash 50%
decreased appetite 24%
NCT01523587 · Phase 3
40 mg
diarrhoea 73.3%
rash 30%
paronychia 23.3%
NCT02208843 · Phase 4 · registry result, not featured evidence
diarrhoea 49.7%
rash 29.9%
paronychia 17.7%
NCT01853826 · Phase 3 · registry result, not featured evidence
diarrhoea 89.3%
rash 70.8%
paronychia 50.1%
NCT01953913 · Phase 3 · registry result, not featured evidence
40 mg
diarrhoea 92.9%
decreased appetite 42.9%
nausea 42.9%
NCT02044380 · Phase 3 · registry result, not featured evidence
diarrhoea 83.5%
rash 54.5%
paronychia 29.6%
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
diarrhoea 53.7%
alopecia 35.1%
asthenia 35.1%
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
40 mg
diarrhoea 88.9%
nausea 66.7%
dry skin 44.4%
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
40 mg
diarrhoea 81.8%
constipation 50%
dermatitis acneiform 36.4%
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
40 mg + 200 mg
diarrhoea 91.7%
decreased appetite 50%
rash 41.7%
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
30 mg + 200 mg
diarrhoea 58.3%
dermatitis acneiform 41.7%
fatigue 33.3%
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
40 mg
diarrhoea 66.7%
rash 33.3%
anaemia 22.2%
NCT02597946 · Phase 2 · registry result, not featured evidence
diarrhea 84.6%
paronyclia 38.5%
erythema multiforme 30.8%
NCT02369484 · Phase 2 · registry result, not featured evidence
40 mg
nausea 100%
rash 100%
stomatitis 100%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 100%
dry skin 83.3%
acne 50%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 93.5%
rash 85.5%
paronychia 67.7%
NCT00711594 · Phase 2 · registry result, not featured evidence
20 mg
dry skin 100%
malaise 100%
rash 100%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 76.8%
rash 73.9%
mucosal inflammation 29%
NCT00796549 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 87.8%
rash 68.3%
decreased appetite 53.7%
NCT00730925 · Phase 2 · registry result, not featured evidence
40 mg
rash 76.2%
diarrhoea 61.9%
decreased appetite 42.9%
NCT01003899 · Phase 2 · registry result, not featured evidence
anemia 83.3%
diarrhea 83.3%
anorexia 66.7%
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
nausea 100%
diarrhea 80%
anemia 60%
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
Afa40+Ctx250
fatigue 75%
nausea 75%
chest pain 50%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Afa40+Ctx500
rash 84.1%
diarrhoea 73%
skin fissures 61.9%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Afa40 Mono
diarrhoea 73%
fatigue 43.2%
rash 37.8%
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
Afa40+Ctx500
rash 47.2%
skin fissures 44.4%
fatigue 38.9%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
head/headache 87.5%
dysphagia 83.3%
infection gr0-2 neut, oral cavity 54.2%
NCT01074177 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Afatinib

PFS 11.17 vs 6.9 Pemetrexed/Cisplatin months40 mg
time to event · months
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 4 more results
11.01 vs 5.59 Gemcitabine / Cisplatin months40mg
NCT01121393 · Phase 3
3.29 vs 1.08 placebo months @ 14wk50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
2.63 vs 1.94 Erlotinib months
NCT01523587 · Phase 3
5.55 vs 2.89 Investigators Choice of Chemotherapy months
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
ORR 56.5% (n=230) vs 22.6% (n=115) Pemetrexed/Cisplatin40 mg
absolute value · percentage points
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
7.4% (n=390) vs 0.5% (n=195) placebo50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Disease Control 90.4% (n=230) vs 80.9% (n=115) Pemetrexed/Cisplatin40 mg
absolute value · percentage points
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival 28.16 vs 28.22 Pemetrexed/Cisplatin months40 mg
time to event · months
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 3 more results
23.1 vs 23.46 Gemcitabine / Cisplatin months40mg
NCT01121393 · Phase 3
7.82 vs 6.77 Erlotinib months
NCT01523587 · Phase 3
12.25 vs 13.08 Investigators Choice of Chemotherapy months
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 10.87 vs 11.73 placebo months @ 52wk50 mg/Day
time to event · months
Final analysis (526 deaths)
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
ORR 50% (n=60)40 mg
responder rate · % of participants
No placebo or comparator arm
NCT02208843 · Phase 4 · registry result, not featured evidence
show 12 more results
0% (n=18)40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
0% (n=38)40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
13% (n=69)50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
11.6% (n=69) @ 8wk50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
13% (n=69) @ 96wk50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
2% (n=41)50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
16.7% (n=12)40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
8.3% (n=12)30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
62% (n=129)
NCT00525148 · Phase 2
8.5% (n=1154)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
17% (n=6)
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
25% (n=4)
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
Clinical Benefit 82.2% (n=129)
responder rate · % of participants
No placebo or comparator arm
NCT00525148 · Phase 2
Duration of Clinical Benefit 18.83 months
time to event · months
No placebo or comparator arm
NCT00525148 · Phase 2 · converted to months from 81.6 weeks as posted
Duration of Response 10.5 months50 mg
time to event · months
No placebo or comparator arm
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 45.5 weeks as posted
show 5 more results
17.65 months*
NCT00525148 · Phase 2 · converted to months from 76.5 weeks as posted
0 monthsAfa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
9 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
3.9 monthsAfa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
5.8 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Time to Response 38.8% (n=129) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT00525148 · Phase 2
show 6 more results
12.4% (n=129) @ 8wk
NCT00525148 · Phase 2
1.6% (n=129) @ 12wk
NCT00525148 · Phase 2
5.4% (n=129) @ 20wk
NCT00525148 · Phase 2
0% (n=129) @ 28wk
NCT00525148 · Phase 2
1.6% (n=129) @ 36wk
NCT00525148 · Phase 2
0% (n=129) @ 44wk
NCT00525148 · Phase 2
PFS 10.94 months40 mg
time to event · months
No placebo or comparator arm
NCT02208843 · Phase 4 · registry result, not featured evidence
show 17 more results
15.4 months40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
9.9 months40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
2.76 months40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
0.94 months*40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence · converted to months from 4.07 weeks as posted
1.95 months*50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 8.43 weeks as posted
3.66 months*50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence · converted to months from 15.86 weeks as posted
2.08 months*40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 9 weeks as posted
3.32 months*30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 14.4 weeks as posted
10.2 months
NCT00525148 · Phase 2
3.15 months
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
3.67 months*
NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 15.9 weeks as posted
5.88 months*
NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 179 days as posted
1.38 months*
NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 42 days as posted
4.2 monthsAfa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
4.6 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
2.7 monthsAfa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
2.9 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Overall Survival 10.02 months40 mg
time to event · months
No placebo or comparator arm
NCT02597946 · Phase 2 · registry result, not featured evidence
show 6 more results
18.4 months50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
11.64 months*50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 50.43 weeks as posted
8.75 months*40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 37.9 weeks as posted
6.14 months*30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 26.6 weeks as posted
26.8 months
NCT00525148 · Phase 2
12.92 months*
NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 56 weeks as posted

+ 38 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afatinib's landscape · Pyrotinib's landscape